Inbred models lead with 37.1% share while mouse models account for 37.5% as pharmaceutical developers prioritize documented strains and repeatable study outcomes

ROCKVILLE, Md., September 15, 2026 — The role of laboratory animals in drug development is being reassessed as pharmaceutical researchers seek more clinically relevant and reproducible preclinical evidence. On April 10, 2025, the U.S. Food and Drug Administration announced a plan to reduce reliance on animal testing for certain drug-development applications, increasing attention on how and where animal models can provide meaningful evidence during research programs.

Against this changing research environment, Fact.MR estimates the global Rat Mouse Model Market at USD 3.5 billion in 2026, up from USD 3.3 billion in 2025. The market is projected to reach USD 6.8 billion by 2036, expanding at a 6.8% CAGR and creating an absolute dollar opportunity of approximately USD 3.3 billion.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15748

Why Are Rat and Mouse Models Still Important in Preclinical Research?

Rat and mouse models remain widely used because they allow researchers to investigate disease biology, drug response, toxicity, efficacy, and biological mechanisms before human testing.

Their value increasingly depends on model selection rather than animal volume alone. Researchers need strains with known genetic backgrounds, documented health status, predictable phenotypes, and sufficient historical evidence to support comparisons across studies.

This is particularly relevant for pharmaceutical companies managing expensive development programs. A poorly matched model can generate inconclusive data and force researchers to repeat experiments, adding both time and cost to development programs.

Fact.MR identifies model reproducibility, pharmaceutical validation requirements, and drug discovery activity as important forces shaping demand through 2036.

Inbred Models Hold 37.1% Share

Inbred models are projected to account for 37.1% of the Product Type segment in 2026, making them the leading category.

Their principal advantage is genetic consistency. Researchers can use animals with highly comparable genetic backgrounds across repeated experiments, reducing one source of biological variation.

C57BL/6 mice are widely used in metabolic, neurological, and immunology research, while BALB/c mice have established applications in antibody and oncology studies. Genetically engineered models provide more targeted options where researchers require particular mutations, gene deletions, or disease traits.

The growing importance of reproducibility also increases the value of strain documentation. Suppliers that can demonstrate provenance and health records have an advantage when pharmaceutical or academic customers qualify new models.

Mouse Models Account for 37.5% of Demand

Mouse models are expected to hold 37.5% of the Model Type segment in 2026, maintaining their leading position.

Mice offer broad strain availability, short breeding cycles, established laboratory protocols, and extensive historical datasets. These characteristics make them suitable for a wide range of research programs.

Immunodeficient mice are important for xenograft and humanized studies, while wild-type mice can provide standardized reference populations. Humanized mice are gaining attention in immuno-oncology, infectious-disease, antibody, and other research programs where greater human biological relevance is required.

Rats remain important where larger tissue samples, cardiovascular research, behavioral studies, or surgical procedures make them more suitable than mice.

Drug Discovery and Development Leads With 30.2%

Drug Discovery & Development is projected to represent 30.2% of the Application segment in 2026.

Pharmaceutical companies use animal models across target identification, candidate selection, efficacy testing, toxicology, and other preclinical stages. Data from these studies can influence whether a development program advances to subsequent stages.

The need for measurable drug responses creates demand for standardized models. Researchers assess variables such as dosage response, biological activity, safety signals, tumor progression, and survival depending on the study design.

Oncology is an important application area. Tumor xenograft and patient-derived models can help researchers investigate treatment response and disease biology before clinical studies.

Pharmaceutical Companies Represent 29.9%

Pharmaceutical companies are forecast to account for 29.9% of the End User segment in 2026.

Drug developers require predictable access to models throughout long-running research programs. A shortage of specific strains or delays in breeding can disrupt study schedules and increase program costs.

Innovator pharmaceutical companies often require specialized models for oncology, rare diseases, immunology, and other complex programs. Generic pharmaceutical companies typically rely more heavily on established strains for toxicology, bioequivalence-related research, and repeatable preclinical testing.

Biotechnology companies and CROs also provide important demand. CROs can influence purchasing decisions because model selection is often integrated with broader preclinical study services.

Direct Sales Lead Distribution at 31.3%

Direct sales are estimated to represent 31.3% of the Distribution Channel segment in 2026.

Direct procurement allows research organizations to communicate directly with suppliers regarding strain history, health records, breeding schedules, age, sex, genetic background, and delivery requirements.

This becomes particularly important for large studies where animals must arrive within defined research windows. Long-term supply agreements can provide additional predictability for recurring programs.

Research-animal distributors remain important for smaller institutions and regions without direct breeder coverage. However, specialized models increasingly require technical support that goes beyond a conventional product transaction.

What Is Driving Rat Mouse Model Market Growth?

Reproducibility is one of the market's strongest demand drivers. Researchers need confidence that an animal model will produce comparable results across repeated experiments.

Drug development pipelines are another major source of demand. As pharmaceutical companies advance candidates through increasingly complex preclinical programs, demand rises for disease-specific, genetically engineered, immunodeficient, and humanized models.

Documentation is becoming equally important. Pharmaceutical customers increasingly review strain provenance, health status, breeding records, and supplier qualification before approving a model for use.

Specialized services provide another opportunity. Custom breeding, colony management, genetic monitoring, and model validation can convert one-time animal purchases into longer-term supplier relationships.

Humanized Models Create Higher-Value Opportunities

Humanized and immunodeficient models represent an important opportunity within the market.

These models can help researchers investigate therapies where conventional laboratory animals do not adequately reproduce aspects of human biology. Their use is particularly relevant to immuno-oncology, infectious diseases, antibody research, and advanced biologic development.

However, these models also require more specialized handling and can cost substantially more than conventional strains. Suppliers therefore need to demonstrate clear study relevance before customers commit to premium models.

Fact.MR identifies specialized inbred grades, humanized and immunodeficient models, and custom breeding services as notable opportunities through 2036.

Validation Burden and Pricing Remain Constraints

The market faces a significant documentation challenge.

Customers may delay procurement when they cannot verify strain provenance, health status, genetic background, or breeding quality. This issue becomes more serious when specialized animals are being used in high-value pharmaceutical programs.

Price sensitivity can also restrict adoption. Early-stage drug programs operate under uncertain development outcomes, making premium animal models harder to justify unless suppliers can demonstrate measurable improvements in study quality.

Limited local support creates another barrier. Shipping delays, breeding schedules, and technical assistance can affect study continuity, particularly in geographically distant markets.

“Rat and mouse model demand depends less on broad research spending and more on whether a model reduces experimental uncertainty. Providers that show strain provenance and health status are expected to hold stronger positions with pharmaceutical and academic customers,” said Shambhu Nath Jha, Sr. Consultant at Fact.MR.

United States Leads Growth at 8.8% CAGR

The United States is projected to record an 8.8% CAGR from 2026 to 2036, the highest growth rate among the countries analyzed by Fact.MR.

The country's large pharmaceutical and biotechnology research base supports sustained demand for laboratory animals and specialized preclinical models. Buyers also place significant emphasis on model documentation and direct supplier support.

Japan follows at 8.1% CAGR, driven by quality-focused research programs and controlled procurement. Germany is expected to grow at 7.5%, supported by institutional research activity and validation-led purchasing.

The United Kingdom is projected at 6.8%, matching the global market CAGR, while Canada is expected to grow at 6.1%. Australia follows at 5.4%, and Brazil at 4.7%.

The geographic spread reflects different research structures. Mature pharmaceutical markets place greater emphasis on supplier qualification and documentation, while developing markets can face stronger distribution and service constraints.

Who Are the Key Companies?

The competitive landscape includes established laboratory-animal suppliers, specialized model developers, and companies providing custom breeding and genetic-engineering services.

Key companies profiled by Fact.MR include The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Janvier Labs, Orient Bio, Inotiv, and Cyagen Biosciences.

The Jackson Laboratory provides extensive mouse-strain resources and research support. Charles River Laboratories supplies standard and specialized models, while Taconic Biosciences maintains a strong position in genetically defined mouse and rat models.

Janvier Labs, Orient Bio, Inotiv, and Cyagen Biosciences strengthen the competitive landscape through regional supply, research services, specialized models, and custom model development.

Competition through 2036 is expected to center on model availability, reproducibility, health documentation, custom breeding capability, and supply reliability rather than animal supply alone.

Market Snapshot

2025 Market Value: USD 3.3 billion
2026 Market Value: USD 3.5 billion
2036 Forecast Value: USD 6.8 billion
CAGR, 2026–2036: 6.8%
Absolute Dollar Opportunity: USD 3.3 billion
Leading Product Type: Inbred Models, 37.1%
Leading Application: Drug Discovery & Development, 30.2%
Leading End User: Pharmaceutical Companies, 29.9%
Leading Distribution Channel: Direct Sales, 31.3%
Leading Model Type: Mouse Models, 37.5%
Fastest-Growing Country: United States, 8.8% CAGR
Japan: 8.1% CAGR
Germany: 7.5% CAGR
United Kingdom: 6.8% CAGR
Canada: 6.1% CAGR
Australia: 5.4% CAGR
Brazil: 4.7% CAGR
Key Companies: The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Janvier Labs, Orient Bio, Inotiv, Cyagen Biosciences
Unlock Actionable Insights from the Complete Report: https://www.factmr.com/report/rat-mouse-model-market

Report Scope and Methodology

Fact.MR's Rat Mouse Model Market study analyzes the market by Product Type, Application, End User, Distribution Channel, Model Type, and Region.

The product analysis covers inbred models, C57BL/6 mice, BALB/c mice, genetically engineered models, knockout and transgenic models, outbred models, disease models, oncology models, neurology models, and humanized models.

Applications include drug discovery and development, preclinical drug screening, efficacy studies, oncology research, tumor xenograft studies, immunology research, vaccine development, neuroscience, toxicology, safety assessment, and regulatory toxicology.

The report covers North America, Latin America, Europe, East Asia, South Asia and Oceania, and the Middle East and Africa, with country-level analysis for the United States, Japan, Germany, the United Kingdom, Canada, Australia, and Brazil.

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews. Fact.MR combines primary interviews with manufacturers, service providers, distributors, end users, procurement teams, and subject-matter experts with desk research covering government statistics, regulatory publications, company information, technical studies, standards, and industry sources.

Explore More Related Studies Published by Fact.MR Research:

Baby Nasal Aspirator Market- https://www.factmr.com/report/baby-nasal-aspirator-market

Buccal Fat Removal Market- https://www.factmr.com/report/buccal-fat-removal-market

Heart Lung Machine Market- https://www.factmr.com/report/heart-lung-machine-market

Vitamin D Therapy Market- https://www.factmr.com/report/vitamin-d-therapy-market

X-Ray Irradiation Market- https://www.factmr.com/report/x-ray-irradiation-market

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, an independent market research and consulting firm providing syndicated research, custom research, and strategic consulting across healthcare, technology, food and beverage, chemicals and materials, industrial goods, consumer goods, and other major industries.

Fact.MR serves clients globally through offices in Rockville, Maryland, and Dublin, Ireland.

Media Contact

Fact.MR
11140 Rockville Pike, Suite 400
Rockville, MD 20852, United States
Tel: +1 (628) 251-1583
Email: [email protected]

Dublin Office:
Suite 9884, 27 Upper Pembroke Street
Dublin 2, Ireland
Tel: +353-1-4434-232

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.